| Human immunodeficiency virus I infection
Evotaz vs Intelence
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Evotaz vs Intelence with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIntelence has a higher rate of injection site reactions vs Evotaz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Intelence but not Evotaz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Evotaz
Intelence
At A Glance
Oral
Once daily
HIV-1 protease inhibitor with CYP3A inhibitor
Oral
Twice daily
NNRTI
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (atazanavir 300 mg/cobicistat 150 mg) orally once daily with food.
Human immunodeficiency virus I infection 200 mg (one 200 mg tablet or two 100 mg tablets) orally twice daily following a meal
Contraindications
- Clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
- Coadministration with strong CYP3A4 inducers
- Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance with narrow therapeutic indices
- Coadministration with alfuzosin
- Coadministration with ranolazine
- Coadministration with dronedarone
- Coadministration with carbamazepine, phenobarbital, phenytoin
- Coadministration with colchicine in patients with hepatic or renal impairment
- Coadministration with rifampin
- Coadministration with apalutamide, encorafenib, irinotecan, ivosidenib
- Coadministration with lurasidone, pimozide
- Coadministration with dihydroergotamine, ergotamine, methylergonovine
- Coadministration with elbasvir/grazoprevir, glecaprevir/pibrentasvir
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with drospirenone/ethinyl estradiol
- Coadministration with lomitapide, lovastatin, simvastatin
- Coadministration with nevirapine
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with indinavir
- Coadministration with triazolam, orally administered midazolam
—
Adverse Reactions
Most common (>=5%) Jaundice, rash
Serious Cardiac conduction abnormalities, rash, effects on serum creatinine, new onset or worsening renal impairment, chronic kidney disease, nephrolithiasis, cholelithiasis, hepatotoxicity, hyperbilirubinemia
Most common (>=2%) Rash, peripheral neuropathy
Serious Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug hypersensitivity reactions including DRESS, hepatic failure, rhabdomyolysis
Postmarketing Fatal cases of toxic epidermal necrolysis and Stevens-Johnson syndrome, severe hypersensitivity reactions including DRESS and hepatic failure
Pharmacology
EVOTAZ is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that prevents viral Gag and Gag-Pol polyprotein processing, and cobicistat, a CYP3A inhibitor that increases atazanavir systemic exposure.
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Evotaz
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Intelence
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Evotaz
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Intelence
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Evotaz
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Intelence
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EvotazView full Evotaz profile
IntelenceView full Intelence profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.